Evaxion, EVX-01, Personalized Cancer Vaccine, Advanced Melanoma, Phase 2 Clinical Trial, ESMO 2026, AI-Immunology, Cancer Immunotherapy, Neoantigens, T-Cell Responses,

COPENHAGEN, Denmark, October 19, 2026 Evaxion A/S (NASDAQ: EVAX), a clinical-stage TechBio company developing immunotherapies using its proprietary AI-Immunology™...